Despite these recent findings, the correlation between MYC-BCL2 double expression and CD19-CAR T cell resistance needs to be further elucidated, as this genomic alteration seems to represent a negative predictive index for newly diagnosed DLBCL rather than a mechanism of resistance specific to CAR T immunotherapy [61]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.